MIT and Harvard Develop Invisible, Off-the-Shelf Immune Cells to Revolutionize Cancer Treatment
TL;DR Summary
MIT and Harvard researchers have developed a new engineered CAR-NK cell therapy that evades immune rejection, potentially enabling off-the-shelf cancer treatments with improved safety and effectiveness, demonstrated successfully in mouse models.
- MIT’s “stealth” immune cells could change cancer treatment forever ScienceDaily
- Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice Nature
- MIT and Harvard Build “Invisible” Immune Cells That Obliterate Cancer SciTechDaily
- Engineered stem cells yield millions of tumor-fighting natural killer cells at reduced cost Medical Xpress
- Yan Leyfman: Advancing “Off-the-Shelf” Allogeneic CAR-NK Cell Therapies Oncodaily
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
5 min
vs 5 min read
Condensed
97%
940 → 31 words
Want the full story? Read the original article
Read on ScienceDaily